Search Results

Adcentrx Therapeutics (“Adcentrx”), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).

Adcentrx Therapeutics (“Adcentrx”) announced today that China National Medical Products Administration (NMPA) has cleared Adcentrx’s Investigational New Drug (IND) application for ADRX-0706 which enables the company to include China-based clinical centers in the ongoing Phase 1a/1b study for the treatment of select advanced solid tumors.

Adcentrx Therapeutics (“Adcentrx”) today announced that preclinical data for ADRX-0706 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.

Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.

Adcentrx Therapeutics today announced the first patient dosed in the Phase 1a/b study of ADRX-0706 for the treatment of advanced solid tumors.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announces the closing of a $38 million Series A+ financing.

Adcentrx Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application of ADRX-0706 for the treatment of select advanced solid tumors.